Article info
PDFClinical and epidemiological research
Extended report
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
- Correspondence to Ronald F. van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, 17176 Stockholm, Sweden; ronald.van.vollenhoven{at}ki.se
Citation
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Publication history
- Received October 19, 2011
- Accepted December 30, 2011
- First published February 15, 2012.
Online issue publication
April 14, 2023
Article Versions
- Previous version (25 October 2017).
- Previous version (25 October 2017).
- Previous version (25 October 2017).
- Previous version (25 October 2017).
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl